September 26, 2019
Curevo Vaccine’s Shingles vaccine candidate CRV-101 well tolerated by healthy adults in study
Curevo Vaccine’s interim trial results showed a promising safety and tolerability profile of the Shingles vaccine in 90 healthy adults ≥18 to <50 were presented in an oral presentation at the 44th annual International Herpesvirus Workshop in Knoxville, Tennessee.